Many sexually transmitted diseases as well as other infections enter by the vaginal route. Providing for a long-acting infection prevention system can reduce exposure and lower the risk of disease. Researchers at Yale University and University of Alabama at Birmingham used PLA-FITC (Cat# AV039) from from PolySciTech Division of Akina, Inc. (www.polyscitech.com) as part of their work in developing mucoadhesive nanoparticles for vaginal protection. This research holds promise to provide for protection from infection. Read more: Grun, Molly K., Praveen Honhar, Yazhe Wang, Samantha Rossano, Minsoo Khang, Hee Won Suh, Krista Fowles et al. "Pilot PET study of vaginally administered bioadhesive nanoparticles in cynomolgus monkeys: Kinetics and safety evaluation." Bioengineering & Translational Medicine (2024): e10661. https://aiche.onlinelibrary.wiley.com/doi/abs/10.1002/btm2.10661
“Long-lasting vaginal dosage forms could improve the therapeutic efficacy of vaginal microbicides, but achieving long-term delivery to the vaginal canal has been a significant challenge. To advance understanding of vaginal dosage retention and biodistribution, we describe a method of noninvasive imaging with 89Zr-labeled bioadhesive nanoparticles (BNPs) in non-human primates. We additionally examined the safety of repeated BNP application. BNPs administered vaginally to cynomolgus monkeys were still detected after 24 h (1.7% retention) and 120 h (0.1% retention). BNPs did not translocate to the uterus or into systemic circulation. Analysis of inflammatory biomarkers in the vaginal fluid and plasma suggest that BNPs are safe and biocompatible, even after multiple doses. BNPs are a promising delivery vehicle for vaginally administered therapeutics. Further studies using the non-human primate imaging materials and methods developed here could help advance clinical translation of BNPs and other long-lasting vaginal dosage forms.”
AV039 (https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AV039#h)
No comments:
Post a Comment